Kenson Ventures
401 Florence Street, Suite 200, Palo Alto, CA, 94301, United States
Overview
Kenson Ventures, LLC ("Kenson Ventures") is a California-based venture investment limited liability company founded in 1999. It is located in scenic Palo Alto, a town 25 miles south of San Francisco and in the hub of Silicon Valley. Kenson Ventures provides seed money/funds and strategic advice to start-ups, partnerships, and established companies focusing in the biotechnology and life science areas. Kenson Ventures also considers and participates in co-investment with other institutions. The range of investment varies from $500,000 to $3 million U.S. dollars. Since Kenson funds are often accompanied by co-investments from affiliated institutions, the actual amount of investment could be much greater than that provided by us. Majority of the investment are made in private companies in the United States. A Kenson Ventures representative normally serves on the board (member of the Board or Business Advisory Board) in which it has a vested interest. We, at Kenson Ventures, understand the challenges of building a successful company. Our team is dedicated in assisting companies with strong growth potential. Our strength is in our knowledge base and industry experiences in building biotechnology companies in the past. When we make an investment, we do our best to provide growth strategy, resources and the contact network to assure success of the company. Kenson Ventures consistently strives to make fruitful investment work. Our primary focus is on emerging-growth companies. We may also make investments in late-stage companies. In the short time since Kenson Ventures' inception, we have been involved in and financed over 20 rapidly growing companies representing a broad spectrum of technology platforms. The engagement of these companies ranges from the development of novel drugs, discovery of genomics-based drug targets and leads, to the development of research tools in molecular and cellular biology. For a listing of our previous and current investments, please visit our Portfolio Companies section.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Advanced Cell Diagnostics
Participated · Series C · Jun 2015
Advanced Cell Diagnostics (ACD) is a Hayward, California–based leader in in situ nucleic acid detection for life science research and clinical diagnostics. Its core product is the proprietary RNAscope® technology for detecting RNA in situ. The company plans to accelerate entry into the research and clinical diagnostics markets and to launch new technology platforms built on RNAscope. Proceeds from the financing will be used to fund those market-entry and product-launch initiatives. ACD completed a $22M Series C equity financing to support this growth. The company is led by Founder, President and CEO Dr. Yuling Luo. Advanced Cell Diagnostics (ACD) is a Hayward, California-based life science research and clinical diagnostics company focused on cell- and tissue-based diagnostic tests for personalized medicine. Its products and services are built on the proprietary RNAscope® technology, a multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. The company raised $12M in Series B financing; backers include New Leaf Venture Partners and Morningside Ventures. ACD intends to use the capital to expand commercial efforts for RNAscope-based products and services into the life science research market and to accelerate RNAscope's entry into the clinical diagnostics market. The company is led by Dr. Yuling Luo, Founder, President and CEO. Advanced Cell Diagnostics is a Hayward, California–based company that develops cell- and tissue-based diagnostic tests. Its products and services are built on RNAscope, a proprietary multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. The company completed the second closing of its Series A equity financing from Morningside Ventures, bringing the total raised in this round to $5.4M. The funds will allow the company to further develop its cell- and tissue-based diagnostic tests. Founder, President and CEO Dr. Yuling Luo said the company will offer development expertise in RNA analysis for biomarker validation and companion diagnostic development in partnership with pharmaceutical and biotechnology companies.
Team
No current team members are available.